FY2024 EPS Estimates for HRMY Boosted by Cantor Fitzgerald

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at Cantor Fitzgerald upped their FY2024 earnings estimates for Harmony Biosciences in a research report issued on Tuesday, February 11th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings per share of $2.55 for the year, up from their prior estimate of $2.53. Cantor Fitzgerald currently has a “Overweight” rating and a $58.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. Cantor Fitzgerald also issued estimates for Harmony Biosciences’ FY2025 earnings at $3.49 EPS.

HRMY has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Harmony Biosciences in a research note on Monday, January 27th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a research report on Tuesday. They set a “buy” rating and a $55.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Harmony Biosciences has an average rating of “Buy” and an average target price of $55.00.

Harmony Biosciences Stock Down 0.7 %

HRMY stock opened at $37.74 on Wednesday. The business has a 50 day moving average of $35.83 and a 200 day moving average of $35.53. The firm has a market cap of $2.15 billion, a PE ratio of 17.89, a price-to-earnings-growth ratio of 0.51 and a beta of 0.80. Harmony Biosciences has a twelve month low of $28.14 and a twelve month high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Insider Transactions at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 1,123 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sandip Kapadia sold 1,775 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $38.05, for a total value of $67,538.75. The disclosure for this sale can be found here. Insiders sold 72,452 shares of company stock worth $2,831,679 over the last three months. 30.80% of the stock is currently owned by company insiders.

Institutional Trading of Harmony Biosciences

Large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its stake in shares of Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares during the last quarter. Mendota Financial Group LLC lifted its position in Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after purchasing an additional 965 shares in the last quarter. CWM LLC grew its holdings in Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the period. KBC Group NV increased its position in Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Harmony Biosciences in the third quarter worth about $74,000. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.